Kangfang Bio-PD-1/CTLA-4 Dual Antibody Approved Global Phase 3 Clinical First-line Treatment for Advanced Cervical Cancer

Source: Guanlan Pharmaceutical

On April 28, Kangfang Bio-Bio announced that the company’s PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) has been approved by the Center for Drug Evaluation (CDE) of the State Drug Administration of China to carry out a randomized, dual A blind, placebo-controlled global phase 3 clinical study to evaluate the effect of cadonilimab plus platinum-containing chemotherapy with or without bevacizumab for the first-line treatment of persistent, recurrent or metastatic cervical cancer.

Cadonilimab is a new and potential next-generation PD-1/CTLA-4 bispecific tumor immunotherapy backbone drug independently developed by Kangfang Bio.

Based on good clinical data, in August 2020, cadonilimab treatment of recurrent or metastatic cervical squamous cell carcinoma after standard treatment was granted fast track qualification by the US FDA.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.

[1]Cadonilimab (PD-1/CTLA-4 dual antibody) was approved for the first-line treatment of advanced cervical cancer global phase III clinical.

▽ attention [drug Mingkang Germany ] micro-channel public number